EMA Consults On Proposed Framework For Patient Preference Studies
Executive Summary
The EMA is inviting feedback on its plans to ratify, with some caveats, a new framework on how to use patient preferences as input in medical product decision-making. The framework was developed under the EU’s public-private Innovative Medicines Initiative.
You may also be interested in...
EU Project Findings To ‘Instil Confidence’ In Using Patient Preference Studies
The European Medicines Agency’s endorsement of a framework that explains how medical device and drug sponsors can use patient preference studies to answer their research questions could help increase confidence in the conduct and acceptability of such studies.
EU Project Findings To ‘Instil Confidence’ In Using Patient Preference Studies
The European Medicines Agency’s endorsement of a framework that explains how drug and medical device sponsors can use patient preference studies to answer their research questions could help increase confidence in the conduct and acceptability of such studies.
Patient Preference Data: Pfizer’s Tanezumab Study Had ‘Flaws’ That Made It ‘Uninformative’
Study showed osteoarthritis patients are more willing to accept risk of joint damage with NGF-inhibitors than dependency associated with opioids, Pfizer said; however, FDA highlighted key flaws in study design, sample population and survey content.